January 2026 in “Open Science Framework” Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.
January 2026 in “Yonsei Medical Journal” Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
November 2025 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
October 2025 in “International Journal of Cosmetic Science” USPlus® DERM may help hair growth and reduce hair loss.
October 2025 in “Journal of the Endocrine Society” Finasteride lowers cholesterol but doesn't reduce heart-related events.
July 2025 in “American Journal on Addictions” Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
Teak leaf extract can help treat hair loss, and its effectiveness varies by geographic origin.
June 2025 in “Journal of Cosmetic Dermatology” Dutasteride 0.5 mg/day is the most effective treatment for male pattern hair loss.
June 2025 in “Pharmaceuticals” Finasteride use may increase suicidality risk, especially in young men.
February 2025 in “Iranian journal of pharmaceutical research”
February 2025 in “Journal of Pre-Clinical and Clinical Research” The combination of finasteride, dutasteride, and minoxidil is generally safe for treating male hair loss with minimal side effects.
November 2024 in “Journal of Family Medicine and Primary Care” 5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
September 2024 in “Health of Man” Low-dose dutasteride effectively and safely promotes hair growth in men with androgenetic alopecia.
September 2024 in “Frontiers in Neuroendocrinology” 5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.
September 2024 in “Chemico-Biological Interactions” Finasteride improves heart function in obese and aging male rats by reducing oxidative stress and p53 protein levels.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
August 2024 in “Latin American Journal of Development” 5α-reductase enzymes are crucial in certain disorders, and while treatment advances exist, more research on SRD5A3 is needed.
July 2024 in “Behavioural Brain Research” Long-term finasteride treatment reduces depression and brain issues in obese male rats.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
June 2024 in “Ecotoxicology and Environmental Safety” Finasteride harms Daphnia magna's reproduction, growth, and metabolism.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
March 2024 in “Journal of the American Academy of Dermatology” Taking medication for hair loss might cause sexual problems.
February 2024 in “Trends in Sciences” Store Tectona grandis leaf extracts in slightly acidic, light-protected conditions for best stability.
January 2024 in “Brazilian Journal of Hair Health” Some plant-based products might treat hair loss with fewer side effects than current medications.
Solanum nigrum may help treat hair loss.
Finasteride harms Daphnia magna's reproduction and metabolism.
December 2023 in “Benha Journal of Applied Sciences” Men with male pattern baldness have higher blood sugar, bad cholesterol, and ZAG protein levels than healthy men.
December 2023 in “International Journal of Pharmaceutics” New nanoparticles deliver plant extracts to hair follicles to treat conditions like hair loss and acne.
December 2023 in “Alzheimer's & dementia” Finasteride may help reduce anxiety and depression in elderly but might cause depression in young men.
December 2023 in “Alzheimer's & Dementia” Long-term use of a drug for hair loss and prostate issues can cause metabolic problems and depression-like behavior in young male rats.